{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:55:31Z","timestamp":1785304531811,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-023-04596-5","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T04:01:53Z","timestamp":1694491313000},"page":"3413-3420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Design and rationale of a single-arm phase II study of neoadjuvant Durvalumab and Gemcitabine associated with Cisplatin or Carboplatin for upper urinary tract urothelial cancer: the iNDUCT trial (NCT04617756)"],"prefix":"10.1007","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct04617756","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Giorgio","family":"Calleris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyamin","family":"Bendjeddou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Masson-Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Audenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Hou\u00e9d\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,12]]},"reference":[{"key":"4596_CR1","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/S00345-016-1928-X\/METRICS","volume":"35","author":"F Soria","year":"2017","unstructured":"Soria F, Shariat SF, Lerner SP, Fritsche HM, Rink M, Kassouf W et al (2017) Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol 35:379\u2013387. https:\/\/doi.org\/10.1007\/S00345-016-1928-X\/METRICS","journal-title":"World J Urol"},{"key":"4596_CR2","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/J.1464-410X.2009.08818.X","volume":"105","author":"G Lughezzani","year":"2010","unstructured":"Lughezzani G, Jeldres C, Isbarn H, Sun M, Shariat SF, Widmer H et al (2010) Temporal stage and grade migration in surgically treated patients with upper tract urothelial carcinoma. BJU Int 105:799\u2013804. https:\/\/doi.org\/10.1111\/J.1464-410X.2009.08818.X","journal-title":"BJU Int"},{"key":"4596_CR3","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1016\/J.EJCA.2009.06.016","volume":"45","author":"G Lughezzani","year":"2009","unstructured":"Lughezzani G, Jeldres C, Isbarn H, Sun M, Shariat SF, Alasker A et al (2009) Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. Eur J Cancer 45:3291\u20133297. https:\/\/doi.org\/10.1016\/J.EJCA.2009.06.016","journal-title":"Eur J Cancer"},{"key":"4596_CR4","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003085","author":"M Pallauf","year":"2023","unstructured":"Pallauf M, D\u2019Andrea D, K\u00f6nig F, Laukthina E, Yanagisawa T, Roupr\u00eat M et al (2023) Diagnostic accuracy of clinical lymph node staging for upper tract urothelial cancer patients: a multicenter, retrospective, observational study. J Urol. https:\/\/doi.org\/10.1097\/JU.0000000000003085","journal-title":"J Urol"},{"key":"4596_CR5","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/JSO.25877","volume":"121","author":"G Rosiello","year":"2020","unstructured":"Rosiello G, Palumbo C, Knipper S, Pecoraro A, Luzzago S, Deuker M et al (2020) Contemporary conditional cancer-specific survival after radical nephroureterectomy in patients with nonmetastatic urothelial carcinoma of upper urinary tract. J Surg Oncol 121:1154\u20131161. https:\/\/doi.org\/10.1002\/JSO.25877","journal-title":"J Surg Oncol"},{"key":"4596_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/J.EURURO.2023.03.013","author":"M Roupr\u00eat","year":"2023","unstructured":"Roupr\u00eat M, Seisen T, Birtle AJ, Capoun O, Comp\u00e9rat EM, Dominguez-Escrig JL et al (2023) European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 update. Eur Urol. https:\/\/doi.org\/10.1016\/J.EURURO.2023.03.013","journal-title":"Eur Urol"},{"key":"4596_CR7","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1634\/THEONCOLOGIST.2015-0440","volume":"21","author":"M Yin","year":"2016","unstructured":"Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA et al (2016) Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis. Oncologist 21:708\u2013715. https:\/\/doi.org\/10.1634\/THEONCOLOGIST.2015-0440","journal-title":"Oncologist"},{"key":"4596_CR8","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","volume":"395","author":"A Birtle","year":"2020","unstructured":"Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT et al (2020) Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet 395:1268\u20131277. https:\/\/doi.org\/10.1016\/S0140-6736(20)30415-3","journal-title":"Lancet"},{"key":"4596_CR9","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1200\/JCO.2021.39.6_SUPPL.455","volume":"39","author":"AJ Birtle","year":"2021","unstructured":"Birtle AJ, Chester JD, Jones RJ, Jenkins B, Johnson M, Catto JW et al (2021) Updated outcomes of POUT: a phase III randomized trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). J Clin Oncol 39:455\u2013455. https:\/\/doi.org\/10.1200\/JCO.2021.39.6_SUPPL.455","journal-title":"J Clin Oncol"},{"key":"4596_CR10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/J.EURURO.2010.06.029","volume":"58","author":"MG Kaag","year":"2010","unstructured":"Kaag MG, O\u2019Malley RL, O\u2019Malley P, Godoy G, Chen M, Smaldone MC et al (2010) Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol 58:581\u2013587. https:\/\/doi.org\/10.1016\/J.EURURO.2010.06.029","journal-title":"Eur Urol"},{"key":"4596_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/J.CRITREVONC.2018.05.005","volume":"128","author":"RW Gregg","year":"2018","unstructured":"Gregg RW, Vera-Badillo FE, Booth CM, Mahmud A, Brundage M, Leveridge MJ et al (2018) Perioperative chemotherapy for urothelial carcinoma of the upper urinary tract: a systematic review and meta-analysis. Crit Rev Oncol Hematol 128:58\u201364. https:\/\/doi.org\/10.1016\/J.CRITREVONC.2018.05.005","journal-title":"Crit Rev Oncol Hematol"},{"key":"4596_CR12","doi-asserted-by":"publisher","first-page":"e1237","DOI":"10.1016\/j.clgc.2018.08.003","volume":"16","author":"N Almassi","year":"2018","unstructured":"Almassi N, Gao T, Lee B, Stein RJ, Haber GP, Ornstein MC et al (2018) Impact of neoadjuvant chemotherapy on pathologic response in patients with upper tract urothelial carcinoma undergoing extirpative surgery. Clin Genitourin Cancer 16:e1237\u2013e1242. https:\/\/doi.org\/10.1016\/j.clgc.2018.08.003","journal-title":"Clin Genitourin Cancer"},{"key":"4596_CR13","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/bju.15346","volume":"128","author":"T Hamaya","year":"2021","unstructured":"Hamaya T, Hatakeyama S, Tanaka T, Kubota Y, Togashi K, Hosogoe S et al (2021) Trends in the use of neoadjuvant chemotherapy and oncological outcomes for high-risk upper tract urothelial carcinoma: a multicentre retrospective study. BJU Int 128:468\u2013476. https:\/\/doi.org\/10.1111\/bju.15346","journal-title":"BJU Int"},{"key":"4596_CR14","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.eururo.2020.07.003","volume":"79","author":"JJ Leow","year":"2021","unstructured":"Leow JJ, Chong YL, Chang SL, Valderrama BP, Powles T, Bellmunt J (2021) Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a 2020 systematic review and meta-analysis, and future perspectives on systemic therapy. Eur Urol 79:635\u2013654. https:\/\/doi.org\/10.1016\/j.eururo.2020.07.003","journal-title":"Eur Urol"},{"key":"4596_CR15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00763","author":"JA Coleman","year":"2023","unstructured":"Coleman JA, Yip W, Wong NC, Sjoberg DD, Bochner BH, Dalbagni G et al (2023) Multicenter phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy for patients with high-grade upper tract urothelial carcinoma. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.22.00763","journal-title":"J Clin Oncol"},{"key":"4596_CR16","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1097\/JU.0000000000000644","volume":"203","author":"V Margulis","year":"2020","unstructured":"Margulis V, Puligandla M, Trabulsi EJ, Plimack ER, Kessler ER, Matin SF et al (2020) Phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery in patients with high grade upper tract urothelial carcinoma. J Urol 203:690\u2013698. https:\/\/doi.org\/10.1097\/JU.0000000000000644","journal-title":"J Urol"},{"key":"4596_CR17","doi-asserted-by":"publisher","first-page":"4051","DOI":"10.21037\/tau-21-47","volume":"10","author":"KM Gust","year":"2021","unstructured":"Gust KM, Resch I, Dndrea D, Shariat SF (2021) Update on systemic treatment of upper tract urothelial carcinoma: a narrative review of the literature. Transl Androl Urol 10:4051\u201361. https:\/\/doi.org\/10.21037\/tau-21-47","journal-title":"Transl Androl Urol"},{"key":"4596_CR18","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMOA2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H et al (2020) Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 383:1218\u20131230. https:\/\/doi.org\/10.1056\/NEJMOA2002788","journal-title":"N Engl J Med"},{"key":"4596_CR19","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","volume":"22","author":"J Bellmunt","year":"2021","unstructured":"Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D et al (2021) Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 22:525\u2013537. https:\/\/doi.org\/10.1016\/S1470-2045(21)00004-8","journal-title":"Lancet Oncol"},{"key":"4596_CR20","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/nejmoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y et al (2021) Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 384:2102\u20132114. https:\/\/doi.org\/10.1056\/nejmoa2034442","journal-title":"N Engl J Med"},{"key":"4596_CR21","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1200\/JCO.18.01148","volume":"36","author":"A Necchi","year":"2018","unstructured":"Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Lucian\u00f2 R et al (2018) Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J Clin Oncol 36:3353\u20133360. https:\/\/doi.org\/10.1200\/JCO.18.01148","journal-title":"J Clin Oncol"},{"key":"4596_CR22","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/S41591-019-0628-7","volume":"25","author":"T Powles","year":"2019","unstructured":"Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, van der Heijden MS et al (2019) Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med 25:1706\u20131714. https:\/\/doi.org\/10.1038\/S41591-019-0628-7","journal-title":"Nat Med"},{"key":"4596_CR23","doi-asserted-by":"publisher","first-page":"10.e1","DOI":"10.1016\/J.UROLONC.2021.05.014","volume":"40","author":"A Necchi","year":"2022","unstructured":"Necchi A, Martini A, Raggi D, Cucchiara V, Colecchia M, Lucian\u00f2 R et al (2022) A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02. Urol Oncol 40:10.e1-10.e6. https:\/\/doi.org\/10.1016\/J.UROLONC.2021.05.014","journal-title":"Urol Oncol"},{"key":"4596_CR24","doi-asserted-by":"publisher","first-page":"292.e1","DOI":"10.1016\/J.UROLONC.2018.12.002","volume":"37","author":"FG Petros","year":"2019","unstructured":"Petros FG, Qiao W, Singla N, Clinton TN, Robyak H, Raman JD et al (2019) Preoperative multiplex nomogram for prediction of high-risk nonorgan-confined upper-tract urothelial carcinoma. Urol Oncol 37:292.e1-292.e9. https:\/\/doi.org\/10.1016\/J.UROLONC.2018.12.002","journal-title":"Urol Oncol"},{"key":"4596_CR25","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/J.EUF.2020.08.001","volume":"7","author":"A Necchi","year":"2021","unstructured":"Necchi A, Madison R, Pal SK, Ross JS, Agarwal N, Sonpavde G et al (2021) Comprehensive genomic profiling of upper-tract and bladder urothelial carcinoma. Eur Urol Focus 7:1339\u20131346. https:\/\/doi.org\/10.1016\/J.EUF.2020.08.001","journal-title":"Eur Urol Focus"},{"key":"4596_CR26","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/J.JURO.2012.05.079","volume":"189","author":"DA Green","year":"2013","unstructured":"Green DA, Rink M, Xylinas E, Matin SF, Stenzl A, Roupret M et al (2013) Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol 189:1214\u20131221. https:\/\/doi.org\/10.1016\/J.JURO.2012.05.079","journal-title":"J Urol"},{"key":"4596_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211045858","author":"J Kaur","year":"2021","unstructured":"Kaur J, Choi W, Geynisman DM, Plimack ER, Ghatalia P (2021) Role of immunotherapy in localized muscle invasive urothelial cancer. Ther Adv Med Oncol. https:\/\/doi.org\/10.1177\/17588359211045858","journal-title":"Ther Adv Med Oncol"},{"key":"4596_CR28","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP et al (2020) Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 21:1574\u20131588. https:\/\/doi.org\/10.1016\/S1470-2045(20)30541-6","journal-title":"Lancet Oncol"},{"key":"4596_CR29","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","volume":"22","author":"T Powles","year":"2021","unstructured":"Powles T, Cs\u0151szi T, \u00d6zg\u00fcro\u011flu M, Matsubara N, G\u00e9czi L, Cheng SYS et al (2021) Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol 22:931\u2013945. https:\/\/doi.org\/10.1016\/S1470-2045(21)00152-2","journal-title":"Lancet Oncol"},{"key":"4596_CR30","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","volume":"395","author":"MD Galsky","year":"2020","unstructured":"Galsky MD, Arija J\u00c1A, Bamias A, Davis ID, de Santis M, Kikuchi E et al (2020) Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 395:1547\u20131557. https:\/\/doi.org\/10.1016\/S0140-6736(20)30230-0","journal-title":"Lancet"},{"key":"4596_CR31","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/J.EURURO.2013.06.049","volume":"65","author":"F Petrelli","year":"2014","unstructured":"Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Vavassori I, Barni S (2014) Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. Eur Urol 65:350\u2013357. https:\/\/doi.org\/10.1016\/J.EURURO.2013.06.049","journal-title":"Eur Urol"},{"key":"4596_CR32","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1158\/1078-0432.CCR-22-2158","volume":"28","author":"G Basile","year":"2022","unstructured":"Basile G, Bandini M, Gibb EA, Ross JS, Raggi D, Marandino L et al (2022) Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial. Clin Cancer Res 28:5107\u20135114. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2158","journal-title":"Clin Cancer Res"},{"key":"4596_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/S00345-012-0939-5","volume":"31","author":"H Fajkovic","year":"2013","unstructured":"Fajkovic H, Cha EK, Xylinas E, Rink M, Pycha A, Seitz C et al (2013) Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. World J Urol 31:5\u201311. https:\/\/doi.org\/10.1007\/S00345-012-0939-5","journal-title":"World J Urol"},{"key":"4596_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJCA.2023.01.004","author":"ACJ van Akkooi","year":"2023","unstructured":"van Akkooi ACJ, Blank C, Eggermont AMM (2023) Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma. Eur J Cancer. https:\/\/doi.org\/10.1016\/J.EJCA.2023.01.004","journal-title":"Eur J Cancer"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-023-04596-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-023-04596-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-023-04596-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T13:04:14Z","timestamp":1709211854000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-023-04596-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,12]]},"references-count":34,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4596"],"URL":"https:\/\/doi.org\/10.1007\/s00345-023-04596-5","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,12]]},"assertion":[{"value":"27 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Morgan Roupr\u00eat declares to be part of the advisory board for UroGen Pharma, Bristol-Myers Squibb, Janssen Pharmaceuticals, Astellas Pharma, Ipsen, and Cepheid; Constance Thibault for AAA, Astellas, AstraZeneca, Ipsen, Janssen, Pfizer, Merck, MSD, BMS, and Seagen; Fran\u00e7ois Audenet for Astellas, Bristol-Myers Squibb, Ipsen, and Pfizer; Yann Neuzillet for Astellas, AstraZeneca, Bayer, BMS, Bouchara Recordati, Ferring, Ipsen, Janssen-Cilag, Merck, MSD, Novartis, and Pfizer; and Nadine Hou\u00e9d\u00e9 for Astra Zeneca, Bayer, Bristol-Myers Squibb, Janssen Pharmaceuticals, and Ipsen. Giorgio Calleris, Lyamin Bendjeddou, Thomas Seisen, Thierry Chevallier, Alexandra Masson-Lecomte, and Evanguelos Xylinas have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not report any personal data and requires no patient consent for publication. All patients enrolled in this study whose protocol is here presented have subscribed a written informed consent in accordance with applicable regulation and ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The present article consists in a narrative review of the literature and in the presentation of a study protocol; therefore, it does not directly involve human participants. The study protocol presented in this article was approved by the appropriate institutional ethics committee, \u201cComit\u00e9 de Protection des Personnes\u201d, and by the \u201cAgence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9\u201d. The authors certify that the study whose protocol is here presented is being performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Trial registration number is NCT04617756 and it is supervised by an independent data monitoring committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and ethics approval"}}]}}